TrIEM

TrIEM:

Leading products ICM-53 is in the early preclinical stage of development. ICM-53 could effectively control tumor growth with low toxicity in rodent studies. Combination with other immune checkpoint blockers further improved anti-tumor efficacy with low toxicity. IND-enabling studies of ICM-53 has been in progress.

ICM-53
  • Integrates B7H3 specificity with an immuno-stimulator cytokine (IL15-IL15RaSushi)
  • Selectively stimulates proliferation of NK cells and CD8+T cells in TILs, sparing PBMC 
  • Demonstrates an improved therapeutic index by focusing cytokine activity within TME
  • Reduces systemic IL15-medicated proliferation potentially lowering toxicity associated with IL-15 administration
  • Cross-activities in both human and NHP
  • Combination with immune IC blockers further enhances antitumor efficacy while maintaining a low side-effect profile
Scroll to Top